L
Liang Zhang
Researcher at University of Texas MD Anderson Cancer Center
Publications - 135
Citations - 5697
Liang Zhang is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Mantle cell lymphoma & Ibrutinib. The author has an hindex of 33, co-authored 110 publications receiving 4866 citations. Previous affiliations of Liang Zhang include Beth Israel Deaconess Medical Center & Harvard University.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
Transcriptome Profiling, Molecular Biological, and Physiological Studies Reveal a Major Role for Ethylene in Cotton Fiber Cell Elongation
Yong-Hui Shi,Shengwei Zhu,Shengwei Zhu,Xizeng Mao,Jianxun Feng,Yong-Mei Qin,Liang Zhang,Jing Cheng,Liping Wei,Zhi-Yong Wang,Zhi-Yong Wang,Yu-Xian Zhu +11 more
TL;DR: The results indicate that ethylene plays a major role in promoting cotton fiber elongation and may promote cell elongation by increasing the expression of sucrose synthase, tubulin, and expansin genes.
Journal ArticleDOI
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Michael L. Wang,Kristie A. Blum,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Dana Lee,Darrin M. Beaupre,Simon Rule +23 more
TL;DR: With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy.
Journal ArticleDOI
Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial
Michael Wang,Luis Fayad,Nicolaus A. Wagner-Bartak,Liang Zhang,Fredrick Hagemeister,Sattva S. Neelapu,Felipe Samaniego,Peter McLaughlin,Michelle A. Fanale,Anas Younes,Fernando Cabanillas,Nathan Fowler,Kate J. Newberry,Luhong Sun,Ken H. Young,Richard E. Champlin,Larry W. Kwak,Lei Feng,Maria Badillo,Maria Teresa Bejarano,Kimberly Hartig,Wendy Chen,Yiming Chen,Catriona Byrne,Neda Bell,Jerome B. Zeldis,Jorge E. Romaguera +26 more
TL;DR: Oral lenalidomide plus rituximab is well tolerated and effective for patients with relapsed or refractory MCL and the primary efficacy endpoint was overall response (complete or partial response).
Journal ArticleDOI
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial.
Michael Wang,Nathan Fowler,Nicolaus A. Wagner-Bartak,Li Feng,Jorge E. Romaguera,Sattva S. Neelapu,Fredrick B. Hagemeister,Michelle A. Fanale,Yasuhiro Oki,Barbara Pro,Jharna N. Shah,Sheeba K. Thomas,Anas Younes,Chitra Hosing,Liang Zhang,Kate J. Newberry,Madhav Desai,N Cheng,Maria Badillo,M Bejarano,Yiming Chen,Ken H. Young,Richard E. Champlin,Larry W. Kwak,Luis Fayad +24 more
TL;DR: Rituximab plus oral lenalidomide is well tolerated and effective for patients with relapsed/refractory DLBCL and TL, and SCT after lenalidOMide–rituximAB is associated with prolonged response duration.